Efficacy and Safety Study of CC-292 Versus Placebo as Co-therapy With Methotrexate in Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
CC-292 is an oral agent that is under clinical development for the treatment of rheumatoid
arthritis an autoimmune inflammatory disorder.
This study will test the clinical effectiveness and safety of an orally (PO) administered
dose of CC-292 compared to placebo in US female patients currently on background Methotrexate
(MTX) with active Rheumatoid Arthritis (RA